EAGLE PHARMACEUTICALS Reports Second Quarter Earnings Results for FY2023
August 15, 2023
🌥️Earnings Overview
On August 8, 2023, EAGLE PHARMACEUTICALS ($NASDAQ:EGRX) released its second quarter financial results of the fiscal year 2023 (ending June 30, 2023). Total revenue for the quarter totaled USD 64.7 million, which was a 12.8% decrease compared to the same quarter from the previous year. In contrast, net income for the quarter increased by 154.6%, amounting to USD 5.2 million.
Share Price
EAGLE PHARMACEUTICALS reported its second quarter earnings results for FY2023 on Tuesday, with its stock opening at $21.5 and closing at $22.9, representing a 4.9% increase from its prior closing price of 21.8. The company also attributed its success to its ongoing efforts to expand its product portfolio, with the introduction of two new drugs making up almost 10% of total sales in the quarter. The company expressed confidence that it will continue to see strong growth in the coming quarters, as it continues to focus on new drug development and international expansion. With a strong balance sheet and an experienced management team in place, EAGLE PHARMACEUTICALS is well-positioned to capitalize on future opportunities in the pharmaceutical industry. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Eagle Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 257.55 | 11.95 | 4.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Eagle Pharmaceuticals. More…
| Operations | Investing | Financing |
| 33.8 | -86.83 | -6.21 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Eagle Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 404.82 | 152.78 | 19.25 |
Key Ratios Snapshot
Some of the financial key ratios for Eagle Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.2% | 71.3% | 13.7% |
| FCF Margin | ROE | ROA |
| 13.1% | 8.9% | 5.4% |
Analysis
As an investor, I am analyzing the financials of EAGLE PHARMACEUTICALS with the assistance of GoodWhale. After reviewing the data, the Star Chart has classified this company as a ‘rhino’, which means it is a company that has achieved moderate revenue or earnings growth. With this in mind, it is important to consider what type of investors may be interested in such a company. GoodWhale has determined that EAGLE PHARMACEUTICALS is strong in profitability, medium in asset, growth and weak in dividend. This data can be used to determine how attractive the company may be to potential investors. Additionally, I have found that EAGLE PHARMACEUTICALS has a high health score of 10/10 considering its cashflows and debt, which demonstrates that the company is capable to safely ride out any crisis without the risk of bankruptcy. More…
Peers
Eagle Pharmaceuticals Inc is a pharmaceutical company that manufactures and sells prescription drugs. The company competes with other pharmaceutical companies, such as Evoke Pharma Inc, Easton Pharmaceuticals Inc, and Innopharmax Inc.
– Evoke Pharma Inc ($NASDAQ:EVOK)
Evoke Pharma Inc is a pharmaceutical company that focuses on the development of drugs for the treatment of gastrointestinal disorders. The company has a market cap of 6.54 million as of 2022 and a return on equity of -103.41%. The company’s products include treatments for conditions such as irritable bowel syndrome and gastroesophageal reflux disease.
– Easton Pharmaceuticals Inc ($OTCPK:EAPH)
Easton Pharmaceuticals Inc is a specialty pharmaceutical company that focuses on developing, acquiring, and commercializing products in the areas of drug delivery, dermatology, and cancer. The company’s market cap as of 2022 is 134.49k, and its ROE is -2.69%. Easton’s products include topical gels, creams, lotions, and solutions for the treatment of conditions such as acne, cold sores, and psoriasis. The company also develops products for the prevention and treatment of skin cancer.
– Innopharmax Inc ($TPEX:4172)
Innopharmax Inc is a pharmaceutical company with a market cap of 985.59M as of 2022 and a Return on Equity of -12.34%. The company focuses on the development and commercialization of novel therapeutics to treat serious and life-threatening illnesses. Some of the company’s products include treatments for cancer, cardiovascular diseases, and infectious diseases.
Summary
Eagle Pharmaceuticals reported strong financial results for its second quarter of fiscal year 2023 (ending June 30, 2023), with total revenue decreasing 12.8% year-over-year but net income increasing 154.6%. This impressive increase in net income was reflected in the stock price, which moved up on the day of the earnings announcement. For investors interested in the pharmaceutical industry, Eagle Pharmaceuticals is a company worth considering given their strong financial performance and potential for growth. With this performance, Eagle looks to be a strong investment opportunity for investors looking for returns in the pharmaceutical sector.
Related Posts
Recent Posts
